Vaxart Inc Stock Today
| VXRT Stock | USD 0.84 0.03 3.45% |
Performance4 of 100
| Odds Of DistressOver 85
|
Vaxart is selling for under 0.84 as of the 19th of April 2024; that is -3.45 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.83. Vaxart has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Vaxart Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of February 2018 | Category Healthcare | Classification Health Care |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 173.86 M outstanding shares of which 17.19 M shares are at this time shorted by private and institutional investors with about 10.91 trading days to cover. More on Vaxart Inc
Moving together with Vaxart Stock
| 0.79 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.66 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.67 | JSPRW | Jasper Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 2nd of May 2024
Vaxart Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vaxart's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vaxart or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Steven Lo | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Vaxart report their recommendations after researching Vaxart's financial statements, talking to executives and customers, or listening in on Vaxart's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Vaxart Inc. The Vaxart consensus assessment is calculated by taking the average forecast from all of the analysts covering Vaxart. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Vaxart's liquidity, profitability, solvency, and operating efficiency, Vaxart Inc may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Vaxart Inc is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vaxart's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vaxart's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaxart's financial leverage. It provides some insight into what part of Vaxart's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vaxart Inc (VXRT) is traded on NASDAQ Exchange in USA. It is located in 170 Harbor Way, South San Francisco, CA, United States, 94080 and employs 109 people. Vaxart is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 146.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vaxart's market, we take the total number of its shares issued and multiply it by Vaxart's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vaxart Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 173.86 M outstanding shares of which 17.19 M shares are at this time shorted by private and institutional investors with about 10.91 trading days to cover.
Vaxart Inc currently holds about 129.55 M in cash with (70.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vaxart Probability Of Bankruptcy
Ownership AllocationVaxart Inc shows a total of 173.86 Million outstanding shares. About 81.0 % of Vaxart outstanding shares are held by general public with 0.96 (%) owned by insiders and only 18.15 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vaxart Ownership Details
Vaxart Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Vaxart jumping above the current price in 90 days from now is under 95%. The Vaxart Inc probability density function shows the probability of Vaxart stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.2176. This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Vaxart will likely underperform. Additionally, vaxart Inc has an alpha of 0.2817, implying that it can generate a 0.28 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Vaxart to move above the current price in 90 days from now is under 95 (This Vaxart Inc probability density function shows the probability of Vaxart Stock to fall within a particular range of prices over 90 days) .
Vaxart Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Vaxart that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vaxart's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vaxart's value.| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2023-12-31 | 176 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 153.5 K | |
| Private Portfolio Partners Llc | 2023-12-31 | 103.2 K | |
| Group One Trading, Lp | 2023-12-31 | 82.8 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 79.1 K | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 78.5 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 78.1 K | |
| Hbk Sorce Advisory Llc | 2023-12-31 | 75.1 K | |
| Ae Wealth Management Llc | 2023-12-31 | 62.2 K | |
| Vanguard Group Inc | 2023-12-31 | 7 M | |
| Geode Capital Management, Llc | 2023-12-31 | 2 M |
Vaxart Historical Income Statement
Vaxart Inc Income Statement is one of the three primary financial statements used for reporting Vaxart's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Vaxart Inc revenue and expense. Vaxart Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Vaxart's Income Tax Expense is comparatively stable compared to the past year. Research Development is likely to gain to about 71.5 M in 2024, whereas Total Revenue is likely to drop slightly above 7 M in 2024. View More FundamentalsVaxart Stock Against Markets
Picking the right benchmark for Vaxart stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vaxart stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vaxart is critical whether you are bullish or bearish towards Vaxart Inc at a given time. Please also check how Vaxart's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vaxart without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Vaxart Corporate Directors
Vaxart corporate directors refer to members of a Vaxart board of directors. The board of directors generally takes responsibility for the Vaxart's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Vaxart's board members must vote for the resolution. The Vaxart board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Michael Finney | Interim Director | Profile | |
| Geoffrey Cox | Independent Director | Profile | |
| John Richard | Independent Director | Profile | |
| Michael Dougherty | Independent Director | Profile |
How to buy Vaxart Stock?
Before investing in Vaxart, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Vaxart. To buy Vaxart stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Vaxart. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Vaxart stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Vaxart Inc stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Vaxart Inc stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Vaxart Inc, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Vaxart Stock please use our How to Invest in Vaxart guide.
Already Invested in Vaxart Inc?
The danger of trading Vaxart Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vaxart is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vaxart. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vaxart Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vaxart Inc is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Vaxart Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Vaxart Inc Stock. Highlighted below are key reports to facilitate an investment decision about Vaxart Inc Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Vaxart Stock analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Vaxart's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaxart. If investors know Vaxart will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaxart listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Revenue Per Share 0.051 | Quarterly Revenue Growth 146.5 | Return On Assets (0.42) | Return On Equity (0.98) |
The market value of Vaxart Inc is measured differently than its book value, which is the value of Vaxart that is recorded on the company's balance sheet. Investors also form their own opinion of Vaxart's value that differs from its market value or its book value, called intrinsic value, which is Vaxart's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaxart's market value can be influenced by many factors that don't directly affect Vaxart's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaxart's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaxart is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaxart's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.